Get the Stockscreener App
0.6152
6.48%
-0.0433
Kala Bio Inc stock is traded at $0.6152, with a volume of 597.48K.
It is down -6.48% in the last 24 hours and down -31.58% over the past month.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
See More
Previous Close:
$0.6585
Open:
$0.637
24h Volume:
597.48K
Relative Volume:
0.08
Market Cap:
$17.13M
Revenue:
$5.75M
Net Income/Loss:
$-38.96M
P/E Ratio:
-0.0493
EPS:
-12.47
Net Cash Flow:
$-32.63M
1W Performance:
+10.78%
1M Performance:
-31.58%
6M Performance:
-88.34%
1Y Performance:
-91.99%
1-Day Range:
$0.6121
$0.655
1-Week Range:
$0.5595
$0.7373
52-Week Range:
$0.51
$20.60
Kala Bio Inc Stock (KALA) Company Profile
Name
Kala Bio Inc
Sector
Industry
Phone
781-996-5252
Address
1167 MASSACHUSETTS AVENUE, ARLINGTON, MA
Compare KALA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KALA
Kala Bio Inc
|
0.6152 | 18.34M | 5.75M | -38.96M | -32.63M | -12.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.84 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.70 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
424.30 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
813.77 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.69 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Kala Bio Inc Stock (KALA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-25 | Downgrade | Mizuho | Outperform → Neutral |
| Sep-29-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-29-25 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Sep-08-25 | Initiated | Mizuho | Outperform |
| Jul-11-25 | Initiated | Ladenburg Thalmann | Buy |
| Mar-30-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Aug-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-14-20 | Downgrade | Jefferies | Buy → Hold |
| Jul-23-20 | Initiated | Northland Capital | Outperform |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| May-27-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-09-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Dec-17-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Mar-14-19 | Initiated | Jefferies | Buy |
View All
Kala Bio Inc Stock (KALA) Latest News
KALA BIO eliminates debt overhang through equity settlements - TipRanks
KALA BIO Signs Multiple Material Agreements - TradingView — Track All Markets
KALA BIO Clears Oxford DebtA Fresh Start Ahead? - Nasdaq
Kala Bio Settles $10.6 Million Debt; Shares Rise After-Hours - marketscreener.com
Kala Bio settles $10.6 million debt with Oxford Finance By Investing.com - Investing.com Nigeria
Kala Bio settles $10.6 million debt with Oxford Finance - Investing.com India
Kala Bio Settles Approximately $10.6 Million Of Debt - TradingView — Track All Markets
KALA BIO Settles Approximately $10.6 million of Debt - The Manila Times
Kala Bio fully settles loan, strengthens balance sheet - MSN
KALA BIO Inc. (KALA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Kala Bio Inc pays $2 million to Oxford Finance LLC as part of settlement agreement - marketscreener.com
KALA BIO Announces Conditional Resignations of Six Directors - TradingView — Track All Markets
Top Penny Stocks To ResearchDecember 4th - MarketBeat
Why Did Indaptus Therapeutics Surge 64% In After-Hours Trading? - Benzinga
Support Test: What insider trading reveals about AAOI stockJuly 2025 Sentiment & High Return Trade Guides - moha.gov.vn
Market Review: How KALA BIO Inc. stock trades before earnings2025 Winners & Losers & Short-Term Swing Trade Alerts - Улправда
Will KALA BIO Inc. stock see PE expansion2025 Growth vs Value & High Win Rate Trade Tips - Улправда
How KALA BIO Inc. stock reacts to bond yieldsJuly 2025 Big Picture & Precise Buy Zone Identification - DonanımHaber
Can KALA BIO Inc. stock deliver sustainable ROEMarket Weekly Review & Growth Focused Stock Reports - DonanımHaber
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Risk Check: Will KALA BIO Inc. stock see PE expansionRisk Management & Fast Exit and Entry Trade Guides - Улправда
How KALA BIO Inc. stock trades before earningsWeekly Market Report & Consistent Income Trade Recommendations - ulpravda.ru
Kala Bio Stock Slides 42% With A 8-Day Losing Spree - Trefis
KALA BIO Announces New CEO and Funding Deal - The Globe and Mail
Oxford Finance Llc Net Worth (2025) - GuruFocus
Kala Bio dismisses Deloitte as auditor, no successor named By Investing.com - Investing.com Canada
KALA BIO announces new CEO and funding deal - MSN
Kala Bio dismisses Deloitte as auditor, no successor named - Investing.com
Kala Bio (NASDAQ: KALA) details dismissal of Deloitte as auditor - Stock Titan
Kala Bio sets annual meeting for January 30, 2026 and updates on investment agreements By Investing.com - Investing.com Nigeria
KALA BIO (Nasdaq: KALA) details Lazar financing shift and 2026 meeting - Stock Titan
Can Sobha Limited Maintain Its Share of Global Market for Its ProductUtilities Sector Analysis & Affordable Portfolio Trading - earlytimes.in
Why Did KALA BIO Shares Jump Over 22% After Hours? - Sahm
What drives KALA BIO Inc stock priceSmall Cap Stock Opportunities & Low Risk Wealth Plans - earlytimes.in
You might want to take a look at Kala Bio Inc (KALA) now - setenews.com
Kala Bio Shares Jump After $6 Million Funding Deal With Investor David Lazar - MSN
Kala Bio enters securities purchase agreement with David Lazar, names him CEO - MSN
KALA BIO closes $10 million registered direct offering - Investing.com India
KALA BIO Raises $10M in Direct Offering - TipRanks
KALA BIO Raises $10 Million From Direct Offering - marketscreener.com
KALA BIO closes $10 million registered direct offering By Investing.com - Investing.com South Africa
KALA BIO Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules - The Manila Times
KALA BIO (NASDAQ: KALA) completes $10 million offering of 10,000,000 shares to repay debt - Stock Titan
Will KALA BIO Inc. stock continue upward momentumMarket Risk Summary & Community Consensus Picks - Newser
Kala Bio raises $10 million in registered direct offering By Investing.com - Investing.com Nigeria
KALA BIO Stock (NASDAQ: KALA): New $10 Million Offering, Debt Deal and Delisting Risk – December 4, 2025 Update - ts2.tech
KALA BIO, Inc. (KALA) Stock: Surges 21.62% Amid Exciting New Offering Announcement - parameter.io
KALA Bio (KALA) Announces $10 Million Direct Stock Offering - GuruFocus
Kala Bio Inc Stock (KALA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Kala Bio Inc Stock (KALA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Reumuth Mary | CHIEF FINANCIAL OFFICER |
Oct 22 '25 |
Sale |
0.83 |
32,230 |
26,751 |
29,873 |
| Reumuth Mary | CHIEF FINANCIAL OFFICER |
Oct 23 '25 |
Sale |
0.82 |
967 |
793 |
28,906 |
| Bazemore Todd | Director |
Oct 22 '25 |
Sale |
0.83 |
47,768 |
39,647 |
35,932 |
| Brazzell Romulus K | SEE REMARKS |
Oct 22 '25 |
Sale |
0.83 |
46,748 |
38,801 |
35,952 |
| Kharabi Darius | CHIEF BUSINESS OFFICER |
Oct 22 '25 |
Sale |
0.83 |
20,806 |
17,269 |
41,760 |
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):